PHASE 2 STUDY OF SACITUZUMAB GOVITECAN-HZIYIN IN PATIENTS WITH PREVIOUSLY TREATED MESOTHELIOMAS

$5,263,281FY2024Defense Health AgencyDOD

Sloan-Kettering Institute For Cancer Research

Investigators